Johns Hopkins investigators published pilot data showing genome‑wide cell‑free DNA (cfDNA) fragmentation and fragmentomic signatures can identify liver fibrosis and cirrhosis, expanding liquid‑biopsy applications beyond oncology. The AI‑driven approach analyzes cfDNA fragmentation patterns and epigenomic signals to infer organ‑specific injury, with early results distinguishing chronic liver disease states from controls. The team, working with Delfi Diagnostics and publishing in Science Translational Medicine, demonstrated the method’s ability to detect disease‑specific genome‑architecture changes and immune‑related signals in blood, opening a pathway to noninvasive monitoring of chronic disease. Translating fragmentomics into validated clinical assays will require larger cohorts and standardized pipelines, but these results mark a step toward multi‑disease blood tests for population screening and monitoring.